Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 4Q

Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

4Q Revenues: $3.8 billion (flat)

4Q Earnings: $961 million (+15%)

FY Revenues: $15.0 billion (+2%)

FY Earnings: $4.2 billion (+33%)

Comments: Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million. Foreign exchange negatively impacted sales by $30 million. Aranesp sales were down 15% to $706 million in the quarter and down 14% to $3.1 billion for the year due to a decline in demand and additional product label changes. Sales of Epogen were $646 million (+1%) and for the year sales were down 1% to $2.5 billion. Combined sales of Neulasta and Neupogen increased 6% to $1.2 billion in the quarter and 9% to $4.7 billion for the year. Sales of Enbrel increased 7% in the quarter to $913 million and 13% to 3.6 billion for the year. R&D expenses were down 2% to $770 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters